You are here

Novo Nordisk

People Are Paying $25 for Wegovy, and It's Going to Keep Making Novo Nordisk Billions

Motley Fool

Thu, 11/9/23 - 09:53 am

Novo Nordisk to discontinue Levemir insulin in U.S. market

Reuters

Wed, 11/8/23 - 09:59 pm

Novo Nordisk warns EU that new rules will push it to expand faster in US

Financial Times

Sun, 11/5/23 - 11:15 pm

Novo, Lilly Weight-Loss Drug Juggernaut Has Nowhere to Go But Up

BioSpace

Sun, 11/5/23 - 11:12 pm

Novo Nordisk shrugs off supply issues with record sales

Pharmaphorum

Thu, 11/2/23 - 11:37 am

Novo Nordisk is concluding research on Wegovy’s impact on osteoarthritis

Stat

Thu, 11/2/23 - 11:35 am

Pfizer’s twice daily pill for obesity hopes to rival Wegovy and Mounjaro

Stat

Thu, 10/26/23 - 11:24 am

Demand for Ozempic and Wegovy Is Through the Roof. Here's Why it Can Go Even Higher.

Motley Fool

Wed, 10/25/23 - 09:51 am

Belgium plans temporary ban on use of Ozempic for weight loss

Yahoo/Reuters

Tue, 10/24/23 - 09:39 am

NASH on the Cusp: An Emerging Market Opportunity

BioSpace

Mon, 10/23/23 - 09:53 am

Viking Therapeutics

Madrigal Pharmaceuticals

Terns Pharmaceuticals

Akero Therapeutics

Hepion Pharmaceuticals

Galmed Pharmaceuticals

GE HealthCare, Novo Nordisk partner to treat diabetes and obesity with ultrasound

Mass Device

Fri, 10/20/23 - 10:14 am

type 2 diabetes

Novo Nordisk, with coffers filling with cash, buys rival to Bayer's kidney drug Kerendia in $1.3B deal

Fierce Biotech

Mon, 10/16/23 - 10:24 am

KBP Biosciences

chronic kidney disease

High-flying Novo Nordisk once again dials up its 2023 sales and profit expectations

Fierce Pharma

Fri, 10/13/23 - 12:04 pm

Fresenius Medical: effect of drugs like Ozempic on patient numbers is neutral

Yahoo/Reuters

Thu, 10/12/23 - 05:24 pm

Fresenius Medical Care

Far More Employers Could Cover Weight Loss Drugs Like Wegovy Next Year—Here’s What That Means For Costs

Forbes

Thu, 10/12/23 - 11:40 am

Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

CP Wire/Businesswire

Wed, 10/11/23 - 11:50 pm

Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Wed, 10/11/23 - 03:40 pm

Novo Ends Semaglutide Kidney Study Early Due to Strong Efficacy Signals

BioSpace

Wed, 10/11/23 - 10:15 am

clinical trials

chronic kidney disease

2 Reasons Why Eli Lilly's Mounjaro Might Beat Novo Nordisk's Ozempic, and 2 Reasons Why It Might Not

Motley Fool

Fri, 10/6/23 - 10:08 am

Here's the Best Big Pharma Stock of the Decade so Far (and It's Not Even Close)

Motley Fool

Fri, 10/6/23 - 10:05 am

Pages